Difference between revisions of "Example orders for Docetaxel (Taxotere) in non-small cell lung cancer"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "'''Use of this site is subject to you reading and agreeing with the terms set forth" to "{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | <span style="font-family:Arial; font-size:200%"> Hello!<br> We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br> Please help us by filling it out!<br> '''Link:''' http://j.mp/2BlBaoQ </span> |}<br>'''Use of this site is subject to you reading and agreeing with the terms set forth") |
Warner-admin (talk | contribs) m (Text replacement - " " to " ") |
||
| (9 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | + | <!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''--> | |
| − | |||
| − | < | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature. | Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature. | ||
| Line 16: | Line 9: | ||
===Example regimen #1=== | ===Example regimen #1=== | ||
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV on day 1 | *[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV on day 1 | ||
| − | **Administer over 30-60 minutes. | + | **Administer over 30-60 minutes. Use non-DEHP tubing/paclitaxel tubing. |
'''21-day cycles''' | '''21-day cycles''' | ||
| − | ====Supportive | + | ====Supportive therapy==== |
| − | *Prochlorperazine (Compazine) 10 mg PO x 1 prn nausea | + | *Prochlorperazine (Compazine) 10 mg PO x 1 prn nausea |
| − | *[[Dexamethasone (Decadron)]] 8 mg PO | + | *[[Dexamethasone (Decadron)]] 8 mg PO twice per day the day before, day of, and day after chemotherapy |
Hydration: | Hydration: | ||
| Line 29: | Line 22: | ||
Monitoring: | Monitoring: | ||
*On day 1 of each cycle: CBC with differential, absolute neutrophil count (ANC), BUN/Cr, alk phos, AST, ALT, total bilirubin, carcinoembryonic antigen | *On day 1 of each cycle: CBC with differential, absolute neutrophil count (ANC), BUN/Cr, alk phos, AST, ALT, total bilirubin, carcinoembryonic antigen | ||
| − | *On cycle 1 day 10, check nadir CBC with differential, absolute neutrophil count (ANC). | + | *On cycle 1 day 10, check nadir CBC with differential, absolute neutrophil count (ANC). Need for further nadir count checks to be determined by degree of cytopenias. |
*Assess for response with CT scan every 3+ cycles depending on symptoms | *Assess for response with CT scan every 3+ cycles depending on symptoms | ||
Outpatient medications: | Outpatient medications: | ||
*[[Dexamethasone (Decadron)]] as described above | *[[Dexamethasone (Decadron)]] as described above | ||
| − | *Lorazepam (Ativan) 0.5 mg PO | + | *Lorazepam (Ativan) 0.5 mg PO every 6 hours prn anxiety, insomnia, nausea |
| − | *Ondansetron (Zofran) 4 mg PO | + | *Ondansetron (Zofran) 4 mg PO every 6 hours prn nausea |
'''Clinical scenario & comments:''' | '''Clinical scenario & comments:''' | ||
| − | *60 year-old lady with stage IV adenocarcinoma of the lung, s/p treatment with first-line therapy for metastatic disease with [[Non-small cell lung cancer#Carboplatin_monotherapy_.26_Pemetrexed_.28Alimta.29|Carboplatin (Paraplatin) & Pemetrexed (Alimta)]], with good response. | + | *60 year-old lady with stage IV adenocarcinoma of the lung, s/p treatment with first-line therapy for metastatic disease with [[Non-small cell lung cancer#Carboplatin_monotherapy_.26_Pemetrexed_.28Alimta.29|Carboplatin (Paraplatin) & Pemetrexed (Alimta)]], with good response. Progressed after maintenance therapy with Pemetrexed (Alimta). |
===Example regimen #2 - dose reduction & neulasta for pancytopenia=== | ===Example regimen #2 - dose reduction & neulasta for pancytopenia=== | ||
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV on day 1 | *[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV on day 1 | ||
| − | **Administer over 30-60 minutes. | + | **Administer over 30-60 minutes. Use non-DEHP tubing/paclitaxel tubing. |
'''21-day cycles''' | '''21-day cycles''' | ||
| − | ====Supportive | + | ====Supportive therapy==== |
*[[Pegfilgrastim (Neulasta)]] 6 mg SC x1 on day 2, 24 hours after completion of day 1 chemotherapy | *[[Pegfilgrastim (Neulasta)]] 6 mg SC x1 on day 2, 24 hours after completion of day 1 chemotherapy | ||
| − | *Prochlorperazine (Compazine) 10 mg PO x 1 prn nausea | + | *Prochlorperazine (Compazine) 10 mg PO x 1 prn nausea |
| − | *[[Dexamethasone (Decadron)]] 8 mg PO | + | *[[Dexamethasone (Decadron)]] 8 mg PO twice per day the day before, day of, and day after chemotherapy |
Hydration: | Hydration: | ||
| Line 56: | Line 49: | ||
Monitoring: | Monitoring: | ||
*On day 1 of each cycle: CBC with differential, absolute neutrophil count (ANC), BUN/Cr, alk phos, AST, ALT, total bilirubin, carcinoembryonic antigen | *On day 1 of each cycle: CBC with differential, absolute neutrophil count (ANC), BUN/Cr, alk phos, AST, ALT, total bilirubin, carcinoembryonic antigen | ||
| − | *Once on day 10-14, check nadir CBC with differential, absolute neutrophil count (ANC). | + | *Once on day 10-14, check nadir CBC with differential, absolute neutrophil count (ANC). Transfuse RBCs as needed. |
*Assess for response with CT scan every 3+ cycles depending on symptoms | *Assess for response with CT scan every 3+ cycles depending on symptoms | ||
Outpatient medications: | Outpatient medications: | ||
*[[Dexamethasone (Decadron)]] as described above | *[[Dexamethasone (Decadron)]] as described above | ||
| − | *Lorazepam (Ativan) 0.5 mg PO | + | *Lorazepam (Ativan) 0.5 mg PO every 6 hours prn anxiety, insomnia, nausea |
| − | *Ondansetron (Zofran) 4 mg PO | + | *Ondansetron (Zofran) 4 mg PO every 6 hours prn nausea |
'''Clinical scenario & comments:''' | '''Clinical scenario & comments:''' | ||
| − | *72 year-old lady with stage IV adenocarcinoma of the lung with bony metastases and history of pathologic fracture, s/p treatment with first-line therapy for metastatic disease with [[Non-small cell lung cancer#Carboplatin_monotherapy_.26_Pemetrexed_.28Alimta.29|Carboplatin (Paraplatin) & Pemetrexed (Alimta)]], who initially responded but them progressed on CT imaging after cycle 5 of therapy. | + | *72 year-old lady with stage IV adenocarcinoma of the lung with bony metastases and history of pathologic fracture, s/p treatment with first-line therapy for metastatic disease with [[Non-small cell lung cancer#Carboplatin_monotherapy_.26_Pemetrexed_.28Alimta.29|Carboplatin (Paraplatin) & Pemetrexed (Alimta)]], who initially responded but them progressed on CT imaging after cycle 5 of therapy. Cycle 1 of therapy was given as above in example #1, but due to significant neutropenia, anemia, and thrombocytopenia (50-60) at nadir blood count, Docetaxel (Taxotere) was dose reduced as above, and Pegfilgrastim (Neulasta) added. In later cycles, neutropenia was not an issue, RBC transfusion need was minimal, and platelet counts were adequate for treatment. |
[[Category:Example chemotherapy order sets]] | [[Category:Example chemotherapy order sets]] | ||
Latest revision as of 02:05, 1 June 2023
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
Docetaxel (Taxotere)
Original references may be found at Docetaxel (Taxotere)
Example regimen #1
- Docetaxel (Taxotere) 75 mg/m2 IV on day 1
- Administer over 30-60 minutes. Use non-DEHP tubing/paclitaxel tubing.
21-day cycles
Supportive therapy
- Prochlorperazine (Compazine) 10 mg PO x 1 prn nausea
- Dexamethasone (Decadron) 8 mg PO twice per day the day before, day of, and day after chemotherapy
Hydration:
- 500 ml NS at KVO rate. Use as running IV for chemotherapy infusion. Give up to 500 ml NS.
Monitoring:
- On day 1 of each cycle: CBC with differential, absolute neutrophil count (ANC), BUN/Cr, alk phos, AST, ALT, total bilirubin, carcinoembryonic antigen
- On cycle 1 day 10, check nadir CBC with differential, absolute neutrophil count (ANC). Need for further nadir count checks to be determined by degree of cytopenias.
- Assess for response with CT scan every 3+ cycles depending on symptoms
Outpatient medications:
- Dexamethasone (Decadron) as described above
- Lorazepam (Ativan) 0.5 mg PO every 6 hours prn anxiety, insomnia, nausea
- Ondansetron (Zofran) 4 mg PO every 6 hours prn nausea
Clinical scenario & comments:
- 60 year-old lady with stage IV adenocarcinoma of the lung, s/p treatment with first-line therapy for metastatic disease with Carboplatin (Paraplatin) & Pemetrexed (Alimta), with good response. Progressed after maintenance therapy with Pemetrexed (Alimta).
Example regimen #2 - dose reduction & neulasta for pancytopenia
- Docetaxel (Taxotere) 60 mg/m2 IV on day 1
- Administer over 30-60 minutes. Use non-DEHP tubing/paclitaxel tubing.
21-day cycles
Supportive therapy
- Pegfilgrastim (Neulasta) 6 mg SC x1 on day 2, 24 hours after completion of day 1 chemotherapy
- Prochlorperazine (Compazine) 10 mg PO x 1 prn nausea
- Dexamethasone (Decadron) 8 mg PO twice per day the day before, day of, and day after chemotherapy
Hydration:
- 500 ml NS at KVO rate. Use as running IV for chemotherapy infusion. Give up to 500 ml NS.
Monitoring:
- On day 1 of each cycle: CBC with differential, absolute neutrophil count (ANC), BUN/Cr, alk phos, AST, ALT, total bilirubin, carcinoembryonic antigen
- Once on day 10-14, check nadir CBC with differential, absolute neutrophil count (ANC). Transfuse RBCs as needed.
- Assess for response with CT scan every 3+ cycles depending on symptoms
Outpatient medications:
- Dexamethasone (Decadron) as described above
- Lorazepam (Ativan) 0.5 mg PO every 6 hours prn anxiety, insomnia, nausea
- Ondansetron (Zofran) 4 mg PO every 6 hours prn nausea
Clinical scenario & comments:
- 72 year-old lady with stage IV adenocarcinoma of the lung with bony metastases and history of pathologic fracture, s/p treatment with first-line therapy for metastatic disease with Carboplatin (Paraplatin) & Pemetrexed (Alimta), who initially responded but them progressed on CT imaging after cycle 5 of therapy. Cycle 1 of therapy was given as above in example #1, but due to significant neutropenia, anemia, and thrombocytopenia (50-60) at nadir blood count, Docetaxel (Taxotere) was dose reduced as above, and Pegfilgrastim (Neulasta) added. In later cycles, neutropenia was not an issue, RBC transfusion need was minimal, and platelet counts were adequate for treatment.